Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Pfizer delivered an earnings beat, raised its 2026 revenue outlook, and has supportive regulatory and pipeline progress. Shares gained 15.3% over 21 sessions and closed at a new period high on August 19.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash Flow Strength ⢠Quarterly Loss Swing ⢠Dividend Pressure Pfizer remains cash-generative and profitable on a trailing annual basis, but the latest quarter swung to losses with elevated leverage and weak dividend coverage, making the shares only moderately attractive at current levels.
Price Behavior
Key Price Behavior Insights: ⢠Higher highs ⢠$26.2 support ⢠Near-term extension Support Level: $26.20 Resistance Level: $27.05 PFE has been in a strong last month uptrend, rising from the mid-$24s to $26.79-$27.05, with $26.2 acting as support but the stock now looking extended near resistance after a sharp rally.
Sentiment & News
Key News Insights: ⢠Q2 Beat ⢠Non-COVID Growth ⢠Pipeline Upside Pfizer is showing a turnaround as Q2 beats, higher 2026 guidance, and stronger non-COVID growth help offset COVID declines and patent-cliff pressure, with pipeline launches supporting sentiment.
AI Summary
Pfizer is no longer just a post-COVID laggard: improving non-COVID growth, launch momentum, and strong free cash flow support the dividend, but the investment remains a hold until those gains clearly outpace the 2026â2028 patent cliff and recurring impairment/legal risks.
Description
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets and distributes prescription medicines and vaccines across a wide range of therapeutic areas, including cardiovascular, oncology, immunology, infectious disease and rare disorders. Its portfolio covers biologics, small molecules, immunotherapies, vaccines and biosimilars, and the company also conducts contract manufacturing and supplies products to wholesalers, hospitals, clinics, pharmacies and government agencies. Founded in 1849, Pfizer is headquartered in New York and maintains strategic collaborations with several pharmaceutical and biotech companies worldwide.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 19 | Aug 26 | PFE | Pfizer Inc. | Pfizer delivered an earnings beat, raised its 2026 revenue outlook, and has supportive regulatory and pipeline progress. Shares gained 15.3% over 21 sessions and closed at a new period high on August 19. | Active | +0.0% |